Cargando…

Bifidobacterium longum RAPO Ameliorates Anti-tumor Efficacy and Immune-Related Adverse Events of Anti-PD-1 Therapy in a Mouse Model of Triple-Negative Breast Cancer

OBJECTIVES: Immune checkpoint inhibitors (ICIs) have been considered as a novel treatment of triple negative breast cancer (TNBC) representing higher risk of early metastasis and relapse. ICIs induce immune-related adverse events (irAEs) including myocarditis, pneumonitis, hepatitis, nephritis, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyeyoon, Oh, Rira, Heo, Ji-Won, Ji, Geun Eog, Park, Myeong Soo, Kim, Sung-Eun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194227/
http://dx.doi.org/10.1093/cdn/nzac068.015
_version_ 1784726672635854848
author Kim, Hyeyoon
Oh, Rira
Heo, Ji-Won
Ji, Geun Eog
Park, Myeong Soo
Kim, Sung-Eun
author_facet Kim, Hyeyoon
Oh, Rira
Heo, Ji-Won
Ji, Geun Eog
Park, Myeong Soo
Kim, Sung-Eun
author_sort Kim, Hyeyoon
collection PubMed
description OBJECTIVES: Immune checkpoint inhibitors (ICIs) have been considered as a novel treatment of triple negative breast cancer (TNBC) representing higher risk of early metastasis and relapse. ICIs induce immune-related adverse events (irAEs) including myocarditis, pneumonitis, hepatitis, nephritis, and colitis, which can cause ICIs discontinuation. Thus, finding treatment strategies to enhance efficacy while reducing irAEs of ICIs is important to improve prognosis and quality of life of cancer patients. We investigated whether combination therapy of anti-PD-1 with Bifidobacterium longum RAPO would affect efficacy and irAEs against TNBC. METHODS: 4T1 tumor-bearing mice were assigned to tumor control, B. longum RAPO (RAPO), Anti-PD-1 (Mono), or Anti-PD-1 + RAPO (Combi) group. Tumor tissues were analyzed by IHC, qRT-PCR, and Affymetrix Mouse Gene 2.0 ST Array followed by functional analysis using IPA®. Heart, lung, liver, kidney, and colon tissues were analyzed by qRT-PCR and Western blot. RESULTS: B. longum RAPO supplementation extended survival of tumor-bearing mice compared with other groups. In the tumor tissue, Combi group showed the increased levels of PD-L1 score, TUNEL positive cells, and anti-tumor M1 cytokines such as IFNγ and CXCL9 compared with Mono group, while pro-tumor M2 cytokines were decreased in Combi group. Functional analysis predicted reduction of cardiac lesion and lung inflammation in Combi group. Consistently, expression of CCL3 and CC5, chemokines associated with cardiac lesion, was reduced in the heart tissue of Combi group. Pro-inflammatory cytokines including IL1β and TNFα were significantly decreased, whereas anti-inflammatory cytokine IL10 was increased in the heart, lung, liver, and kidney tissues of Combi group than Mono group. Myeloperoxidase, a pro-inflammatory enzyme released by activated neutrophils, was also significantly reduced in the liver tissue of Combi group. Colonic expression of IL10 and tight junction proteins such as ZO-1 and occludin was significantly increased in Combi group than Mono group. CONCLUSIONS: B. longum RAPO supplementation not only enhances anti-tumor efficacy also improves the risk of irAEs in mice with TNBC, suggesting that combination therapy with B. longum RAPO might be a promising therapeutic strategy for Anti-PD-1 immunotherapy. FUNDING SOURCES: BIFIDO CO., NRF (2020R1C1C1007553 to S-EK).
format Online
Article
Text
id pubmed-9194227
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91942272022-06-14 Bifidobacterium longum RAPO Ameliorates Anti-tumor Efficacy and Immune-Related Adverse Events of Anti-PD-1 Therapy in a Mouse Model of Triple-Negative Breast Cancer Kim, Hyeyoon Oh, Rira Heo, Ji-Won Ji, Geun Eog Park, Myeong Soo Kim, Sung-Eun Curr Dev Nutr Nutritional Immunology and Inflammation/Immunometabolism OBJECTIVES: Immune checkpoint inhibitors (ICIs) have been considered as a novel treatment of triple negative breast cancer (TNBC) representing higher risk of early metastasis and relapse. ICIs induce immune-related adverse events (irAEs) including myocarditis, pneumonitis, hepatitis, nephritis, and colitis, which can cause ICIs discontinuation. Thus, finding treatment strategies to enhance efficacy while reducing irAEs of ICIs is important to improve prognosis and quality of life of cancer patients. We investigated whether combination therapy of anti-PD-1 with Bifidobacterium longum RAPO would affect efficacy and irAEs against TNBC. METHODS: 4T1 tumor-bearing mice were assigned to tumor control, B. longum RAPO (RAPO), Anti-PD-1 (Mono), or Anti-PD-1 + RAPO (Combi) group. Tumor tissues were analyzed by IHC, qRT-PCR, and Affymetrix Mouse Gene 2.0 ST Array followed by functional analysis using IPA®. Heart, lung, liver, kidney, and colon tissues were analyzed by qRT-PCR and Western blot. RESULTS: B. longum RAPO supplementation extended survival of tumor-bearing mice compared with other groups. In the tumor tissue, Combi group showed the increased levels of PD-L1 score, TUNEL positive cells, and anti-tumor M1 cytokines such as IFNγ and CXCL9 compared with Mono group, while pro-tumor M2 cytokines were decreased in Combi group. Functional analysis predicted reduction of cardiac lesion and lung inflammation in Combi group. Consistently, expression of CCL3 and CC5, chemokines associated with cardiac lesion, was reduced in the heart tissue of Combi group. Pro-inflammatory cytokines including IL1β and TNFα were significantly decreased, whereas anti-inflammatory cytokine IL10 was increased in the heart, lung, liver, and kidney tissues of Combi group than Mono group. Myeloperoxidase, a pro-inflammatory enzyme released by activated neutrophils, was also significantly reduced in the liver tissue of Combi group. Colonic expression of IL10 and tight junction proteins such as ZO-1 and occludin was significantly increased in Combi group than Mono group. CONCLUSIONS: B. longum RAPO supplementation not only enhances anti-tumor efficacy also improves the risk of irAEs in mice with TNBC, suggesting that combination therapy with B. longum RAPO might be a promising therapeutic strategy for Anti-PD-1 immunotherapy. FUNDING SOURCES: BIFIDO CO., NRF (2020R1C1C1007553 to S-EK). Oxford University Press 2022-06-14 /pmc/articles/PMC9194227/ http://dx.doi.org/10.1093/cdn/nzac068.015 Text en © The Author 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Nutritional Immunology and Inflammation/Immunometabolism
Kim, Hyeyoon
Oh, Rira
Heo, Ji-Won
Ji, Geun Eog
Park, Myeong Soo
Kim, Sung-Eun
Bifidobacterium longum RAPO Ameliorates Anti-tumor Efficacy and Immune-Related Adverse Events of Anti-PD-1 Therapy in a Mouse Model of Triple-Negative Breast Cancer
title Bifidobacterium longum RAPO Ameliorates Anti-tumor Efficacy and Immune-Related Adverse Events of Anti-PD-1 Therapy in a Mouse Model of Triple-Negative Breast Cancer
title_full Bifidobacterium longum RAPO Ameliorates Anti-tumor Efficacy and Immune-Related Adverse Events of Anti-PD-1 Therapy in a Mouse Model of Triple-Negative Breast Cancer
title_fullStr Bifidobacterium longum RAPO Ameliorates Anti-tumor Efficacy and Immune-Related Adverse Events of Anti-PD-1 Therapy in a Mouse Model of Triple-Negative Breast Cancer
title_full_unstemmed Bifidobacterium longum RAPO Ameliorates Anti-tumor Efficacy and Immune-Related Adverse Events of Anti-PD-1 Therapy in a Mouse Model of Triple-Negative Breast Cancer
title_short Bifidobacterium longum RAPO Ameliorates Anti-tumor Efficacy and Immune-Related Adverse Events of Anti-PD-1 Therapy in a Mouse Model of Triple-Negative Breast Cancer
title_sort bifidobacterium longum rapo ameliorates anti-tumor efficacy and immune-related adverse events of anti-pd-1 therapy in a mouse model of triple-negative breast cancer
topic Nutritional Immunology and Inflammation/Immunometabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194227/
http://dx.doi.org/10.1093/cdn/nzac068.015
work_keys_str_mv AT kimhyeyoon bifidobacteriumlongumrapoamelioratesantitumorefficacyandimmunerelatedadverseeventsofantipd1therapyinamousemodeloftriplenegativebreastcancer
AT ohrira bifidobacteriumlongumrapoamelioratesantitumorefficacyandimmunerelatedadverseeventsofantipd1therapyinamousemodeloftriplenegativebreastcancer
AT heojiwon bifidobacteriumlongumrapoamelioratesantitumorefficacyandimmunerelatedadverseeventsofantipd1therapyinamousemodeloftriplenegativebreastcancer
AT jigeuneog bifidobacteriumlongumrapoamelioratesantitumorefficacyandimmunerelatedadverseeventsofantipd1therapyinamousemodeloftriplenegativebreastcancer
AT parkmyeongsoo bifidobacteriumlongumrapoamelioratesantitumorefficacyandimmunerelatedadverseeventsofantipd1therapyinamousemodeloftriplenegativebreastcancer
AT kimsungeun bifidobacteriumlongumrapoamelioratesantitumorefficacyandimmunerelatedadverseeventsofantipd1therapyinamousemodeloftriplenegativebreastcancer